Disease Modifying Effect of Chronic Oral Treatment with a Neurotrophic Peptidergic Compound in a Triple Transgenic Mouse Model of Alzheimer's Disease

This study investigated the potential of P021, a neurotrophic peptidergic compound derived from CNTF, as a disease-modifying treatment for Alzheimer's disease using the triple-transgenic mouse model (3xTg-AD), which develops both amyloid and tau pathology. The mice received chronic oral treatment with P021 in their diet over several months.

The results demonstrated that P021 rescued the cognitive deficits observed in 3xTg-AD mice, restoring spatial learning and memory as assessed by the Morris water maze. At the cellular level, treatment promoted hippocampal neurogenesis and synaptic plasticity, normalizing levels of markers such as synaptophysin and MAP2.

Notably, P021 acted on both major pathological hallmarks of Alzheimer's:

• Reduction of tau hyperphosphorylation at key disease-associated epitopes
• Decrease in amyloid beta plaques in the brain
• Increased expression of BDNF (brain-derived neurotrophic factor)

The proposed mechanism involves inhibition of the neurogenesis-inhibitory pathway mediated by leucine-rich repeat and Ig domain-containing 1 (LINGO-1) and activation of neurotrophic signaling. The fact that the compound is orally active makes it particularly promising for clinical development, as most neurotrophic peptides require invasive administration.

This study was one of the first to demonstrate that a neurotrophic peptide can simultaneously modify multiple aspects of Alzheimer's pathology in an animal model, with significant implications for the development of preventive therapies.